

22783 U.S. PTO
022604

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

22141 U.S. PTO
10/787367
022604

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

26 February 2004

Date of Deposit

Signature


EL 964822627 US

Express Mail No.

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: USAV2001/0143 US CNT
INVENTORS: GRAUPE, et al.

TITLE: **Novel Compounds and Compositions
as Cathepsin Inhibitors**

APPLICATION ELEMENTS

1. *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. Specification Total Pages
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (*if filed*)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. Drawing(s) (35 U.S.C. 113) Total Sheets
4. Oath or Declaration Total Pages
 - a. Newly unexecuted (original or copy)
 - b. Copy from a prior application (37 CFR § 1.63(d))
 - i. DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).
5. Power of Attorney Total Pages
 - a. Newly executed (original or copy)
 - b. Copy from a prior application (37 CFR § 1.63(d))
6. Microfiche Computer Program (*Appendix*)

7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
- Computer Readable Copy
 - Paper Copy (identical to computer copy)
 - Statement verifying identity of above copies

If a CONTINUING Application, check appropriate box, and supply the requisite information:

Continuation Divisional Continuation-in-part
 of prior application no: PCT/US02/29323, filed September 16, 2002,
 Examiner _____, Group/Art Unit _____.
 (The cross reference has been/will be inserted on page one of the specification).

This application claims the benefit of U.S. Provisional Application No. 60/322,318,
 filed September 14, 2001. (The cross reference has been/will be inserted on page one of the
 specification).

Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior
 application is enclosed.)

The entire disclosure of the prior application, from which a copy of the oath or declaration is
 supplied, is considered as being part of the disclosure of the accompanying application and is
 hereby incorporated by reference therein.


ACCOMPANYING APPLICATION PARTS

- Assignment Papers (*cover sheet & document(s)*)
 - 37 CFR §3.73(b) Statement
(when there is an assignee)
 - Verified English Translation Document (*if applicable*)
 - Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS Citations
 - Preliminary Amendment
 - Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
 - *Small Entity Statement(s) Statement filed in prior application,
(PTO/SB/09-12) Status still proper and desired
 - Certified Copy of Priority Document(s)
(if foreign priority is claimed)
 - Other: Application Data Sheet
-

CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label

005487
<i>(Insert Customer No. or Attach bar code label here)</i>


 George G. Wang, Reg. No. 41,419
 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
 Patent Department
 Route #202-206 / P.O. Box 6800
 Bridgewater, New Jersey 08807-0800
 Telephone (908) 231-2843
 Telefax (908) 231-2626
 Aventis Docket No. USAV2001/0143 US CNT

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 770.00)

Complete if Known

Application Number	Not Yet Known
Filing Date	Herewith
First Named Inventor	GRAUPE
Examiner Name	
Group / Art Unit	
Attorney Docket No.	USA2001/0143 US CNT

METHOD OF PAYMENT (check all that apply)

 Check Credit Card Money Other None Order
 Deposit Account

Deposit Account Number 18-1982

Deposit Account Name Aventis Pharmaceuticals Inc.

The Commissioner is authorized to: (check all that apply)

-
- Charge fee(s) indicated below
-
- Credit any overpayments
-
-
- Charge any additional fee(s) during the pendency of this application
-
-
- Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account

FEE CALCULATION

1. BASIC FILING FEE

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)
1001	770	2001	375
1002	340	2002	165
1003	530	2003	260
1004	770	2004	375
1005	160	2005	80
SUBTOTAL (1)		(\$770.00)	

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

	Extra Claims	Fee from below	Fee Paid
Total Claims	16	-20**=	=
Independent	3	- 3**=	=
Claims			
Multiple Dependent		=	

Large Entity	Small Entity	Fee Description
Fee Code	Fee (\$)	Fee Description
1202	18	2202 9 Claims in excess of 20
1201	86	2201 42 Independent claims in excess of 3
1203	290	2203 140 Multiple dependent claim, if not paid
1204	86	2204 42 *Reissue independent claims over original patent
1205	18	2205 9 *Reissue claims in excess of 20 and over original patent
SUBTOTAL (2)		(\$0.00)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)
1051	130	2051	65 Surcharge - late filing fee or oath
1052	50	2052	25 Surcharge - late provisional filing fee or cover sheet
1053	130	1053	130 Non-English Specification
1812	2,520	1812	2,520 For filing a request for reexamination
1804	920*	1804	920* Requesting publication of SIR prior to Examiner action
1805	1,840*	1805	1,840* Requesting publication of SIR after Examiner action
1251	110	2251	55 Extension for reply within first month
1252	420	2252	205 Extension for reply within second month
1253	950	2253	465 Extension for reply within third month
1254	1,480	2254	725 Extension for reply within fourth month
1255	2,010	2255	985 Extension for reply within fifth month
1401	330	2401	160 Notice of Appeal
1402	330	2402	160 Filing a brief in support of an appeal
1403	290	2403	140 Request for oral hearing
1451	1,510	1451	1,510 Petition to institute a public use proceeding
1452	110	2452	55 Petition to revive - unavoidable
1453	1,330	2453	650 Petition to revive - unintentional
1501	1,330	2501	650 Utility issue fee (or reissue)
1502	480	2502	235 Design issue fee
1503	640	2503	315 Plant issue fee
1460	130	1460	130 Petitions to the Commissioner
1807	50	1807	50 Petitions related to provisional applications
1806	180	1806	180 Submission of Information Disclosure Stmt
8021	40	8021	40 Recording each patent assignment per property (times number of properties)
1809	770	2809	375 Filing a submission after final rejection (37 CFR § 1.129(a))
1810	770	2810	375 For each additional invention to be examined (37 CFR § 1.129(b))
1801	770	2801	375 Request for Continued Examination (RCE)
1802	900	1802	900 Request for expedited examination of a design application
Other fee (specify)			
*Reduced by Basic Filing Fee Paid		SUBTOTAL (3) (\$ 0.00)	

**or number previously paid, if greater; For Reissues, see above

SUBTOTAL (3) (\$ 0.00)

SUBMITTED BY

Complete (If applicable)

Name (Print/Type)	George G. Wang, Reg. No. 41,419	Registration No. (Attorney/Agent)	41,419	Telephone	(908) 231-2843
Signature				Date	February 26, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Aventis Pharmaceuticals Inc. template